首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1517635

口服固體製劑合約製造市場- 按產品（片劑、膠囊、粉末）、類型（立即、延遲和控釋）、治療領域（腫瘤、心血管、感染、代謝）、服務、最終用途、全球預測（2024年） - 2032)

Oral Solid Dosage Contract Manufacturing Market - By Product (Tablet, Capsule, Powder), Type (Immediate, Delayed, & Controlled Release), Therapeutic area (Oncology, Cardiovascular, Infectious, Metabolic), Service, End-use, Global Forecast (2024 - 2032)

出版日期: 2024年04月24日 | 出版商:

Global Market Insights Inc. | 英文 195 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

口服固體劑型合約製造市場規模預計在2024 年至2032 年期間複合年成長率將達到5.6%。組織(CMO)降低成本，提高生產效率，專注於研發活動等核心能力。對於那些希望在不投資大量生產設施的情況下擴大經營規模的中小型製藥公司來說，這一點尤其突出。

對學名藥的需求也將影響市場的成長。隨著品牌藥物的專利到期，為了滿足全球醫療保健需求，學名藥的生產激增。口服固體劑型是最常用的藥物之一，因為它們提供配方開發、法規遵循和生產規模擴大方面的專業知識。技術和品質標準的不斷進步，以確保一致的產品品質和遵守嚴格的監管要求，也刺激了市場的成長。例如，2024 年 4 月，Lupin 在獲得 FDA 批准後在美國推出了米拉貝隆緩釋片（25 毫克）。

整個產業分為產品、類型、治療領域、服務、最終用途和地區。

從產品來看，膠囊領域的口服固體製劑合約製造市場預計到 2032 年將大幅成長，因為膠囊作為製藥公司和消費者的首選劑型越來越受歡迎。膠囊具有許多優點，包括易於吞嚥、更好的生物利用度以及能夠封裝多種藥物製劑，包括粉末、顆粒和液體。這種多功能性使它們成為各種治療應用的理想選擇。

在服務方面，API製造領域的口服固體製劑合約製造業預計將在2024年至2032年期間產生可觀的收入。這是因為 API（活性藥物成分）在藥物功效和配方中發揮關鍵作用。隨著製藥公司努力開發更有效、更有針對性的療法，對符合嚴格監管標準的高品質 API 的需求不斷增加。

亞太地區口服固體製劑合約製造市場將在 2024 年至 2032 年期間產生利潤豐厚的成長。這歸因於印度和中國製造商提供的巨大成本優勢，與西方國家相比，它們以更低的成本提供高品質的產品。在醫療保健基礎設施和研發活動投資增加的支持下，製藥業的快速擴張也刺激了對合約製造服務的需求。人口眾多且不斷成長，加上醫療保健支出不斷增加和慢性病的流行，進一步增加了對負擔得起且可獲得的藥物的需求，推動了區域行業的擴張。

產業生態系統分析
產業影響力
- 成長動力
  - CDMO 擴大採用外包製造活動
  - 對學名藥的需求不斷增加
  - 製藥公司與 CDMO 之間的策略合作夥伴關係不斷增加
- 產業陷阱與挑戰
  - 品質控制挑戰
  - 智慧財產權問題
成長潛力分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
平板電腦
膠囊
粉末
顆粒劑
其他產品

第 6 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
立即發布
延遲發布
控制釋放

第 7 章：市場估計與預測：按治療領域，2021 - 2032 年

主要趨勢
腫瘤學
心血管疾病
代謝紊亂
神經系統疾病
傳染性疾病
胃腸道疾病
其他治療領域

第 8 章：市場估計與預測：按服務分類，2021 - 2032 年

主要趨勢
藥品開發
填充成品製造
原料藥製造
包裝和標籤
其他應用

第 9 章：市場估計與預測：依最終用途，2021 - 2032 年

主要趨勢
大型企業
中小型企業

第 10 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Aenova Group
AbbVie Contract Manufacturing (AbbVie Inc.)
Boehringer Ingelheim International GmbH
Catalent, Inc.
Corden Pharma International
Jubilant Pharmova Limited
Lonza
NextPharma Technologies
Patheon Pharma Services (Thermo Fisher Scientific Inc.)
Siegfried Holding AG

簡介目錄

Product Code: 9169

Oral solid dosage contract manufacturing market size is expected to record 5.6% CAGR between 2024 and 2032. Lately, pharmaceutical companies are increasingly outsourcing the production of oral solid dosage forms, such as tablets, capsules, and powders to contract manufacturing organizations (CMOs) to reduce costs, improve production efficiency, and focus on core competencies like R&D activities. This is particularly prominent among small to mid-sized pharmaceutical firms looking to scale operations without investing in extensive manufacturing facilities.

The demand for generic drugs will also influence the market growth. As patents for branded drugs expire, there is a surge in the production of generic versions to meet the healthcare demands worldwide. Oral solid dosage forms are among the most prescribed medications as they offer expertise in formulation development, regulatory compliance, and manufacturing scale-up. Rising advancements in technology and quality standards to ensure consistent product quality and adherence to stringent regulatory requirements are also stimulating the market growth. For instance, in April 2024, Lupin unveiled Mirabegron extended-release tablets (25 mg) in the U.S. after approval from FDA.

The overall industry is segmented into product, type, therapeutic area, service, end-use, and region.

Based on product, the oral solid dosage contract manufacturing market from the capsules segment is expected to witness substantial growth rate through 2032 due to its increasing popularity as a preferred dosage form for both pharmaceutical companies and consumers. Capsules offer numerous advantages, including ease of swallowing, better bioavailability, and the ability to encapsulate a wide range of drug formulations, including powders, granules, and liquids. This versatility makes them ideal for a variety of therapeutic applications.

In terms of service, the oral solid dosage contract manufacturing industry from the API manufacturing segment is slated to generate notable revenue during 2024-2032. This is due to the critical role played by APIs (active pharmaceutical ingredients) in drug efficacy and formulation. As pharmaceutical companies strive to develop more effective and targeted therapies, there is an increasing demand for high-quality APIs that meet stringent regulatory standards.

Asia Pacific oral solid dosage contract manufacturing market will generate lucrative growth during 2024-2032. This is attributed to the substantial cost advantages offered by manufacturers in India and China, which provide high-quality production at lower costs compared to Western countries. The rapid expansion of the pharmaceutical industry, supported by increasing investments in healthcare infrastructure and R&D activities, is also fueling the demand for contract manufacturing services. The large and growing population, coupled with rising healthcare expenditure and the prevalence of chronic diseases, is further increasing the need for affordable and accessible medications, driving the regional industry expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising adoption of CDMOs for outsourcing manufacturing activities
  - 3.2.1.2 Increasing demand for generic drugs
  - 3.2.1.3 Growing number of strategic partnerships between pharmaceutical companies and CDMOs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Quality control challenges
  - 3.2.2.2 Intellectual property concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Tablets
5.3 Capsules
5.4 Powders
5.5 Granules
5.6 Other products

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Immediate release
6.3 Delayed release
6.4 Controlled release

Chapter 7 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oncology
7.3 Cardiovascular diseases
7.4 Metabolic disorders
7.5 Neurological disorders
7.6 Infectious diseases
7.7 Gastrointestinal diseases
7.8 Other therapeutic areas

Chapter 8 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Drug product development
8.3 Fill finish product manufacturing
8.4 API manufacturing
8.5 Packaging and labelling
8.6 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Large size companies
9.3 Medium & small size companies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa